Gadolinium News
Reports find increased risk of NSF with Omniscan
Reports from several scientific and legal sources indicate that Omniscan, the most widely used brand of gadolinium MRI contrast dye, may be more dangerous to patients than others that are on the market. Contrast dyes containing gadolinium are used during MRI exams to help doctors view the brain and other parts of the body. More »
Gadolinium dye makers facing almost 400 lawsuits
Documents filed recently in federal court have revealed that the makers of gadolinium-based MRI contrast dyes are facing a total of 391 federal and state gadolinium lawsuits brought by patients. These individuals have alleged that they developed a condition known as nephrogenic systemic fibrosis after receiving an MRI with gadolinium, causing them to suffer severe and possibly deadly side effects.
First deadline to file a gadolinium lawsuit approaching soon
Gadolinium lawyers representing patients who developed the disease nephrogenic systemic fibrosis after receiving an MRI with contrast dye say that time may be running out for some individuals to file a gadolinium lawsuit in their case. According to these attorneys, the first statute of limitations deadline for some gadolinium lawsuit will pass on June 6, 2008. After this date, some patients who developed nephrogenic systemic fibrosis due to gadolinium exposure may lose their legal right to file a lawsuit.
Gadolinium lawsuit filed in Colorado
A Colorado woman who had kidney disease has filed a lawsuit against the manufacturers of a type of contrast dye used in MRI scans. Donna Wetherbee’s gadolinium lawsuit alleges that she developed painful, open sores on her legs after being injected with an MRI contrast dye that contained gadolinium.
Gadolinium dye linked to allergic reactions
Researchers have discovered that patients who are given a type of contrast dye used in MRI or MRA exams may experience allergic-like reactions, even when given anti-allergy drugs. Doctors at the University of Michigan Health Systems in Ann Arbor said that pre-medicating patients with corticosteroids or antihistamines did not prevent some from experiencing a reaction to a contrast dye called gadolinium.
‘Black-box’ warning approved for MRI dye
The Food and Drug Administration has announced the addition of a new “black-box” warning to the labels of a type of contrast agent used with MRI or MRA exams. The agency had previously announced in May that it would add the warning to the five products sold in the U.S. which contain gadolinium—Omniscan, OptiMARK, Magnevist, ProHance or MultiHance.
Tenn. couple files MRI dye problems lawsuit
A Tennessee couple has filed a lawsuit over problems suffered by the husband after receiving an injectable dye during an MRI procedure. Jerry and Lynne Hensley allege that his injection with a dye containing gadolinium caused him to develop a debilitating condition know as nephrogenic systemic fibrosis (NSF). The couple says that because of his preexisting kidney failure, the manufactures of the contrast dye should have warned Jerry Hensley that gadolinium-based dyes were especially dangerous for patients with kidney problems.
FDA issues warning about MRI dye
The Food and Drug Administration has asked the manufacturers of a type of dye used in MRIs to add a “black-box” warning to their products. The agency says that the dyes, a contrast agent containing gadolinium, can lead to a serious condition known as nephrogenic systemic fibrosis (NSF), or nephrogenic fibrosing dermopathy (NFD). Patients who develop these conditions after an MRI may experience a thickening of the skin or other organs, which can cause joint pain or stiffness and can be fatal.
FDA warns of potential for problems after MRI, MRA exam
The Food and Drug Administration has issued a public health advisory about the risk of a dangerous kidney disease for patients who are injected with a type of contrast dye during an MRI or MRA exam. The agency says that patients who receive an injection with a contrast agent containing gadolinium could develop nephrogenic systemic fibrosis, also called nephrogenic fibrosing dermopathy.